RATIONALE: Aeroallergen sensitization and virus-induced wheezing are risk factors for asthma development during early childhood, but the temporal developmental sequence between them is incompletely understood. OBJECTIVE: To define the developmental relationship between aeroallergen sensitization and virus-induced wheezing. METHODS: A total of 285 children at high risk for allergic disease and asthma were followed prospectively from birth. The timing and etiology of viral respiratory wheezing illnesses were determined, and aeroallergen sensitization was assessed annually for the first 6 years of life. The relationships between these events were assessed using a longitudinal multistate Markov model. MEASUREMENTS AND MAIN RESULTS: Children who were sensitized to aeroallergens had greater risk of developing viral wheeze than nonsensitized children (hazard ratio [HR], 1.9; 95% confidence interval [CI], 1.2-3.1). Allergic sensitization led to an increased risk of wheezing illnesses caused by human rhinovirus (HRV) but not respiratory syncytial virus. The absolute risk of sensitized children developing viral wheeze was greatest at 1 year of age; however, the relative risk was consistently increased at every age assessed. In contrast, viral wheeze did not lead to increased risk of subsequent allergic sensitization (HR, 0.76; 95% CI, 0.50-1.1). CONCLUSIONS: Prospective, repeated characterization of a birth cohort demonstrated that allergic sensitization precedes HRV wheezing and that the converse is not true. This sequential relationship and the plausible mechanisms by which allergic sensitization can lead to more severe HRV-induced lower respiratory illnesses support a causal role for allergic sensitization in this developmental pathway. Therefore, therapeutics aimed at preventing allergic sensitization may modify virus-induced wheezing and the development of asthma.
RATIONALE: Aeroallergen sensitization and virus-induced wheezing are risk factors for asthma development during early childhood, but the temporal developmental sequence between them is incompletely understood. OBJECTIVE: To define the developmental relationship between aeroallergen sensitization and virus-induced wheezing. METHODS: A total of 285 children at high risk for allergic disease and asthma were followed prospectively from birth. The timing and etiology of viral respiratory wheezing illnesses were determined, and aeroallergen sensitization was assessed annually for the first 6 years of life. The relationships between these events were assessed using a longitudinal multistate Markov model. MEASUREMENTS AND MAIN RESULTS:Children who were sensitized to aeroallergens had greater risk of developing viral wheeze than nonsensitized children (hazard ratio [HR], 1.9; 95% confidence interval [CI], 1.2-3.1). Allergic sensitization led to an increased risk of wheezing illnesses caused by human rhinovirus (HRV) but not respiratory syncytial virus. The absolute risk of sensitized children developing viral wheeze was greatest at 1 year of age; however, the relative risk was consistently increased at every age assessed. In contrast, viral wheeze did not lead to increased risk of subsequent allergic sensitization (HR, 0.76; 95% CI, 0.50-1.1). CONCLUSIONS: Prospective, repeated characterization of a birth cohort demonstrated that allergic sensitization precedes HRV wheezing and that the converse is not true. This sequential relationship and the plausible mechanisms by which allergic sensitization can lead to more severe HRV-induced lower respiratory illnesses support a causal role for allergic sensitization in this developmental pathway. Therefore, therapeutics aimed at preventing allergic sensitization may modify virus-induced wheezing and the development of asthma.
Authors: Lily S Subrata; Joelene Bizzintino; Emilie Mamessier; Anthony Bosco; Katherine L McKenna; Matthew E Wikström; Jack Goldblatt; Peter D Sly; Belinda J Hales; Wayne R Thomas; Ingrid A Laing; Peter N LeSouëf; Patrick G Holt Journal: J Immunol Date: 2009-07-20 Impact factor: 5.422
Authors: Peter D Sly; Attilio L Boner; Bengt Björksten; Andy Bush; Adnan Custovic; Philippe A Eigenmann; James E Gern; Jorrit Gerritsen; Eckard Hamelmann; Peter J Helms; Robert F Lemanske; Fernando Martinez; Soren Pedersen; Harald Renz; Hugh Sampson; Erika von Mutius; Ulrich Wahn; Patrick G Holt Journal: Lancet Date: 2008-09-20 Impact factor: 79.321
Authors: William W Busse; Wayne J Morgan; Peter J Gergen; Herman E Mitchell; James E Gern; Andrew H Liu; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Jacqueline A Pongracic; James F Chmiel; Suzanne F Steinbach; Agustin Calatroni; Alkis Togias; Katherine M Thompson; Stanley J Szefler; Christine A Sorkness Journal: N Engl J Med Date: 2011-03-17 Impact factor: 91.245
Authors: Michelle A Gill; Gagan Bajwa; Tiffany A George; Caroline C Dong; Irene I Dougherty; Nan Jiang; Vanthaya N Gan; Rebecca S Gruchalla Journal: J Immunol Date: 2010-04-21 Impact factor: 5.422
Authors: Daniel J Jackson; Ronald E Gangnon; Michael D Evans; Kathy A Roberg; Elizabeth L Anderson; Tressa E Pappas; Magnolia C Printz; Wai-Ming Lee; Peter A Shult; Erik Reisdorf; Kirsten T Carlson-Dakes; Lisa P Salazar; Douglas F DaSilva; Christopher J Tisler; James E Gern; Robert F Lemanske Journal: Am J Respir Crit Care Med Date: 2008-06-19 Impact factor: 21.405
Authors: Marrah E Lachowicz-Scroggins; Homer A Boushey; Walter E Finkbeiner; Jonathan H Widdicombe Journal: Am J Respir Cell Mol Biol Date: 2010-01-15 Impact factor: 6.914
Authors: Anne Kotaniemi-Syrjänen; Raija Vainionpää; Tiina M Reijonen; Matti Waris; Kaj Korhonen; Matti Korppi Journal: J Allergy Clin Immunol Date: 2003-01 Impact factor: 10.793
Authors: Amy S Feldman; Yuan He; Martin L Moore; Marc B Hershenson; Tina V Hartert Journal: Am J Respir Crit Care Med Date: 2015-01-01 Impact factor: 21.405
Authors: Amy S Feldman; Tina V Hartert; Tebeb Gebretsadik; Kecia N Carroll; Patricia A Minton; Kimberly B Woodward; Emma K Larkin; Eva Kathryn Miller; Robert S Valet Journal: Pediatr Allergy Immunol Pulmonol Date: 2015-06-01 Impact factor: 1.349